Skip to main content
Erschienen in: World Journal of Surgery 5/2020

03.01.2020 | Original Scientific Report

A Real-World, Population-Based Analysis of the Outcomes of Colorectal Cancer Patients with Isolated Synchronous Liver or Lung Metastases Treated with Metastasectomy

verfasst von: Hani Oweira, Arianeb Mehrabi, Christoph Reissfelder, Omar Abdel-Rahman

Erschienen in: World Journal of Surgery | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Objective

To assess the survival outcomes among a contemporary cohort of colorectal cancer patients with isolated synchronous liver or lung metastases treated with or without surgical resection of the metastases.

Methods

Surveillance, epidemiology and end results database has been accessed and cases with isolated liver or lung metastases diagnosed 2010–2015 have been accessed. Kaplan–Meier survival estimates were used to compare overall survival among patients who had or had not undergone metastasectomy. Multivariable Cox regression analysis was then used to assess the impact of metastasectomy on colorectal cancer-specific survival.

Results

A total of 16,372 patients with colorectal cancer with isolated liver or lung metastases (M1a disease) were included in the current analysis (including 14,832 patients with isolated liver metastases and 1540 patients with isolated lung metastases). Patients who had undergone surgical resection of liver metastases have better overall survival compared to patients who had not undergone surgical resection of liver metastases (median overall survival: 38.0 months vs. 13.0 months; P < 0.001). Likewise, patients who had undergone surgical resection of lung metastases have better overall survival compared to patients who had not undergone surgical resection of lung metastases (median overall survival: 45.0 months vs. 19.0 months; P < 0.001). In a multivariable Cox regression analysis and among patients with isolated liver metastases, surgery to the metastases was associated with a reduced hazard of death (hazard ratio (HR) 0.567; 95% CI 0.529–0.609; P < 0.001). Likewise, and among patients with isolated lung metastases, surgery to the metastases was associated with a reduced hazard of death (HR 0.482; 95% CI 0.349–0.665; P < 0.001).

Conclusion

In a contemporary cohort, metastasectomy seems to be associated with improvement in overall and cancer-specific survival among patients with isolated synchronous liver or lung metastases from colorectal cancer. Whether this survival difference is totally ascribed to the effect of metastasectomy or it is the fact that patients who were eligible for surgical resection have limited disease extent and better medical profile (thus, leading to better survival) is unclear from such a population-based study.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Abdel-Rahman O, Karachiwala H (2019) Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. Int J Colorectal Dis 34(10):1741–1747CrossRef Abdel-Rahman O, Karachiwala H (2019) Impact of age on toxicity and efficacy of 5-FU-based combination chemotherapy among patients with metastatic colorectal cancer; a pooled analysis of five randomized trials. Int J Colorectal Dis 34(10):1741–1747CrossRef
2.
Zurück zum Zitat Abdel-Rahman O (2019) Effect of body mass index on 5-FU-based chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer; a pooled analysis of 5 randomized trials. Clin Colorectal Cancer 18:e385–e393CrossRef Abdel-Rahman O (2019) Effect of body mass index on 5-FU-based chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer; a pooled analysis of 5 randomized trials. Clin Colorectal Cancer 18:e385–e393CrossRef
3.
Zurück zum Zitat Abdel-Rahman O (2019) Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. Clin Colorectal Cancer. 18(2):110–5.e2CrossRef Abdel-Rahman O (2019) Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. Clin Colorectal Cancer. 18(2):110–5.e2CrossRef
4.
Zurück zum Zitat Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A et al (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15(6):601–611CrossRef Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A et al (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15(6):601–611CrossRef
5.
Zurück zum Zitat Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14(12):1208–1215CrossRef Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P et al (2013) Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 14(12):1208–1215CrossRef
6.
Zurück zum Zitat Ampollini L, Gnetti L, Goldoni M, Viani L, Faedda E, Campanini N et al (2017) Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival. J Thorac Dis. 9(Suppl12):S1282–S1290CrossRef Ampollini L, Gnetti L, Goldoni M, Viani L, Faedda E, Campanini N et al (2017) Pulmonary metastasectomy for colorectal cancer: analysis of prognostic factors affecting survival. J Thorac Dis. 9(Suppl12):S1282–S1290CrossRef
7.
Zurück zum Zitat Beppu T, Sakamoto Y, Hayashi H, Baba H (2015) Perioperative chemotherapy and hepatic resection for resectable colorectal liver metastases. Hepatobiliary surgery and nutrition. 4(1):72–75PubMedPubMedCentral Beppu T, Sakamoto Y, Hayashi H, Baba H (2015) Perioperative chemotherapy and hepatic resection for resectable colorectal liver metastases. Hepatobiliary surgery and nutrition. 4(1):72–75PubMedPubMedCentral
8.
Zurück zum Zitat Cokmert S, Ellidokuz H, Demir L, Fuzun M, Astarcioglu I, Aslan D et al (2014) Survival outcomes of liver metastasectomy in colorectal cancer cases: a single-center analysis in Turkey. Asian Pac J Cancer Prev. 15(13):5195–5200CrossRef Cokmert S, Ellidokuz H, Demir L, Fuzun M, Astarcioglu I, Aslan D et al (2014) Survival outcomes of liver metastasectomy in colorectal cancer cases: a single-center analysis in Turkey. Asian Pac J Cancer Prev. 15(13):5195–5200CrossRef
9.
Zurück zum Zitat Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR et al (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 202(3):468–475CrossRef Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR et al (2006) Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 202(3):468–475CrossRef
10.
Zurück zum Zitat Zabaleta J, Aguinagalde B, Fuentes MG, Bazterargui N, Izquierdo JM, Hernandez CJ et al (2011) Survival after lung metastasectomy for colorectal cancer: importance of previous liver metastasis as a prognostic factor. Eur J Surg Oncol. 37(9):786–790CrossRef Zabaleta J, Aguinagalde B, Fuentes MG, Bazterargui N, Izquierdo JM, Hernandez CJ et al (2011) Survival after lung metastasectomy for colorectal cancer: importance of previous liver metastasis as a prognostic factor. Eur J Surg Oncol. 37(9):786–790CrossRef
11.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975–2016 varying) - Linked To County Attributes - Total U.S., 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission. Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975–2016 varying) - Linked To County Attributes - Total U.S., 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission.
12.
Zurück zum Zitat Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A et al (2017) Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 23(10):1872–1880CrossRef Oweira H, Petrausch U, Helbling D, Schmidt J, Mannhart M, Mehrabi A et al (2017) Prognostic value of site-specific metastases in pancreatic adenocarcinoma: A Surveillance Epidemiology and End Results database analysis. World J Gastroenterol. 23(10):1872–1880CrossRef
13.
Zurück zum Zitat Oweira H, Petrausch U, Helbling D, Schmidt J, Mehrabi A, Schob O et al (2017) Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. Expert Rev Gastroenterol Hepatol 11:698–701 Oweira H, Petrausch U, Helbling D, Schmidt J, Mehrabi A, Schob O et al (2017) Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. Expert Rev Gastroenterol Hepatol 11:698–701
Metadaten
Titel
A Real-World, Population-Based Analysis of the Outcomes of Colorectal Cancer Patients with Isolated Synchronous Liver or Lung Metastases Treated with Metastasectomy
verfasst von
Hani Oweira
Arianeb Mehrabi
Christoph Reissfelder
Omar Abdel-Rahman
Publikationsdatum
03.01.2020
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 5/2020
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-019-05353-9

Weitere Artikel der Ausgabe 5/2020

World Journal of Surgery 5/2020 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.